Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Shenzhen Quadrivalent Influenza Vaccine
NCT03430089Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2019
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Shenzhen Quadrivalent Inactivated Influenza Vaccine in influenza (5 arms), sponsored by Sanofi. Primary endpoint: Occurrence of serious adverse reactions or Grade 3 non-serious adverse reactions at 28 days. Started Feb 2019; status: completed.
02
Drugs
Shenzhen Quadrivalent Inactivated Influenza Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03430089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430089.